<DOC>
	<DOCNO>NCT00614380</DOCNO>
	<brief_summary>The primary objective trial ass efficacy safety fix dose combination telmisartan 40 mg / amlodipine 5 mg ( T40/A5 ) telmisartan 80 mg / amlodipine 5 mg ( T80/A5 ) long-term open-label treatment .</brief_summary>
	<brief_title>Open Label Study Telmisartan Amlodipine Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. patient age least 18 year 2. diagnosis essential hypertension blood pressure adequately control enrolment precede trial . 3. failure respond six week treatment Amlodipine 5 mg runin period precede trial . 1. premenopausal woman surgically sterile ; nursing pregnant ; practise acceptable mean birth control plan continue use acceptable mean birth control throughout study 2. development medical condition precede trial investigator 's opinion could worsen treatment either Telmisartan 40 mg/Amlodipine 5 mg Telmisartan 80 mg/Amlodipine 5 mg 3. discontinuation precede trial adverse event reason 4. know suspected secondary hypertension 5. mean seat Systolic Blood Pressure = &gt; 180 mmHg and/or mean seat Diastolic Blood Pressure = &gt; 120 mmHg visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>